BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
269.45
+7.30 (+2.78%)
At close: 4:00PM EDT

269.45 0.00 (0.00%)
After hours: 4:43PM EDT

Stock chart is not supported by your current browser
Previous Close262.15
Open262.70
Bid269.45 x 100
Ask271.07 x 300
Day's Range262.27 - 274.39
52 Week Range244.28 - 370.57
Volume2,252,481
Avg. Volume1,805,164
Market Cap57.006B
Beta1.13
PE Ratio (TTM)22.60
EPS (TTM)11.92
Earnings DateApr 23, 2018 - Apr 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est371.82
Trade prices are not sourced from all markets
  • Biogen Posts Double-Digit Profits, Has Cash to Burn
    Motley Fool49 minutes ago

    Biogen Posts Double-Digit Profits, Has Cash to Burn

    Spinal muscular atrophy drug Spinraza makes up for declines in the biotech's multiple sclerosis drug franchise.

  • Biogen-Ionis Expansion Builds on Spinraza Success
    Market Realist3 hours ago

    Biogen-Ionis Expansion Builds on Spinraza Success

    On April 20, Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced the expansion of their strategic collaboration to develop drug candidates targeted at a range of neurological diseases. This key move builds on the productive collaboration between the two companies that led to the development of Spinraza, the first and only approved treatment for patients with spinal muscular atrophy, along with two antisense drug candidates that are currently under development.

  • Barrons.com4 hours ago

    Biotech Bounceback: Amgen, Biogen Gain Believers

    On another down day for the market, biotech is a bright spot: Shares of Amgen (AMGN) have reversed earlier losses after reporting first-quarter earnings, and Biogen (BIIB) is rising. Amgen said it earned $3.47 a share on revenue of $5.55 billion, while analysts were looking for EPS of $3.25 on revenue of $5.44 billion. Credit Suisse's Alethia Young reiterated a Neutral rating Amgen, but she has a $194 price target, comfortably above the stock's current levels.

  • Benzinga5 hours ago

    Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises

    The Street’s becoming increasingly — albeit reluctantly — bullish on Biogen Inc (NASDAQ: BIIB ). “While we have all the enthusiasm that goes with catching a falling knife here, we believe BIIB shares are ...

  • Performance Update on Biogen’s Multiple Sclerosis Drugs
    Market Realist5 hours ago

    Performance Update on Biogen’s Multiple Sclerosis Drugs

    In 1Q18, Biogen’s (BIIB) Tecfidera generated revenues of $987 million compared to $958 million in 1Q17. In 1Q18 in the US and international markets, Tecfidera generated revenues of $729 million and $258 million, respectively, compared to $751 million and $207 million, respectively, in 1Q17. In 1Q18, in the US and international markets, Tecfidera witnessed a 12% decline and a 6% growth, respectively, on a quarter-over-quarter basis.

  • How Did Biogen’s Spinraza Perform in 1Q18?
    Market Realist7 hours ago

    How Did Biogen’s Spinraza Perform in 1Q18?

    In 1Q18, Biogen’s (BIIB) Spinraza generated revenues of $364 million compared to $47 million in 1Q17 and $363 million in 4Q17. In 1Q18 in the US and international markets, Spinraza generated revenues of $188 million and $176 million, respectively, compared to $46 million and $1 million, respectively, in 1Q17. Spinraza is used in the treatment of individuals with spinal muscular atrophy.

  • A Look at Biogen’s Performance in 1Q18
    Market Realist8 hours ago

    A Look at Biogen’s Performance in 1Q18

    In 1Q18, Biogen (BIIB) generated revenues of $3.1 billion compared to $2.8 billion in 1Q17. That was an ~11% growth on a year-over-year (or YoY) basis and a ~5% decline on a quarter-over-quarter basis.

  • MarketWatch9 hours ago

    Spinraza’s flat sales rattle investors but Biogen sees momentum for key rare-disease therapy

    The expensive rare disease therapy Spinraza has quickly become a critical part of Biogen’s performance, but the latest sales figures were sluggish.

  • Investopedia11 hours ago

    Why Biogen's Stock Rebound Is Good News for Biotechs

    An analysis of the technical chart of Biogen Inc. ( BIIB) shows the stock could be set to rebound by about 7%, giving shares the chance to rise back towards $282 from its price of roughly $263, a jump of about 7.5%. Biogen shares were up by roughly 1% on April 24, after the company reported better than expected first-quarter earnings per share, and revenue that was in line with estimates. Biogen's stock has been hit hard in 2018, with the stock down by nearly 30%, since late January peaking near $370 per share. Biogen shares fell to an intraday low of $251, a significant technical support level, that goes back to July of 2016.

  • Thomson Reuters StreetEvents11 hours ago

    Edited Transcript of BIIB earnings conference call or presentation 24-Apr-18 12:30pm GMT

    Q1 2018 Biogen Inc Earnings Call

  • The Wall Street Journal16 hours ago

    [$$] Biogen Investors Are Losing Patience

    Biotech giant Biogen needs to quickly rebuild its new drug pipeline, a risky and expensive undertaking, to win investors back.

  • Biogen Rallies After Spinraza, Multiple Sclerosis Revenue Come In Light
    Investor's Business Dailyyesterday

    Biogen Rallies After Spinraza, Multiple Sclerosis Revenue Come In Light

    Biogen on Tuesday reported adjusted income of $6.05 per share on $3.1 billion in sales.

  • Why Ionis Pharmaceuticals Crashed Today
    Motley Foolyesterday

    Why Ionis Pharmaceuticals Crashed Today

    Two news events in one day have the biotech seeing red.

  • InvestorPlaceyesterday

    Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?

    It’s a busy week for pharmaceutical companies, with Eli Lilly And Co (NYSE:LLY), Biogen Inc (NASDAQ:BIIB), and Amgen, Inc. (NASDAQ:AMGN) having released their earnings report today. For Eli Lilly stock, investors sought a definitive sign where the renowned firm was headed. Since early summer of 2015, Eli Lilly stock gyrated wildly between bullish and bearish phases, only to come out dead even.

  • Reutersyesterday

    Biogen's revenue misses as Spinraza sales disappoint

    Drugmaker Biogen Inc's quarterly revenue missed analysts' estimates on Tuesday as it had disappointing sales of its promising drug Spinraza to treat spinal muscular atrophy because fewer new patients used the expensive treatment. Biogen shares fell in early trade after sales of Spinraza as well as its flagship drug, Tecfidera, were weaker than expected, underscoring investor concerns about the company's drug development prospects.

  • Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
    Zacksyesterday

    Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

    Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

  • Investopediayesterday

    How Does Biogen Make its Money?

    Biogen is a healthy biotechnology company producing a stream of illness-fighting drugs. Its big sellers treat MS, and it is diversifying its product line.

  • MarketWatchyesterday

    Biogen stock drops 2% after Q1 sales miss

    Biogen Inc. shares dropped 2.4% in premarket trade Tuesday after the company reported a first-quarter sales miss. Earnings for the latest quarter rose to $1.2 billion, or $5.54 per share, from $748 million, ...

  • Reutersyesterday

    Biogen quarterly profit jumps on higher Spinraza sales

    Drug developer Biogen Inc reported a 57 percent jump in quarterly profit on Tuesday, helped by higher sales of its spinal muscular atrophy drug, Spinraza. Net income attributable to shareholders rose to ...

  • Business Wireyesterday

    Biogen Reports Quarterly Revenues of $3.1 Billion

    Biogen Inc. today reported first quarter 2018 financial results, including:

  • ACCESSWIREyesterday

    Biogen Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Biogen Inc. (NASDAQ: BIIB ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 8:30 AM Eastern Time. To listen ...

  • MarketWatch2 days ago

    Ahead of earnings, Biogen’s Ionis deal perplexes

    Biogen just announced a $1 billion deal, but it may not be enough to make investors happy.

  • Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
    Market Realist2 days ago

    Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected

    Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.

  • Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
    Zacks2 days ago

    Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN

    Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.

  • Benzinga2 days ago

    The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO

    Below is a list of notable corporate events for the week beginning April 23. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on AMD Monday ...